Several PFF Registry-based Studies Presented at American Thoracic Society Conference

First Patient Dosed in Phase 2b Study Testing Inhaled RVT-1601 for IPF Cough

The first patient was dosed in a Phase 2b clinical trial investigating the safety and effectiveness of Respivant Biosciences’ inhalation therapy candidate RVT-1601 for idiopathic pulmonary fibrosis patients with persistent cough. Respivant Biosciences also has launched a new website — IPFcough.com — to increase awareness about the effects of cough…